Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma

HK Gan; DA Reardon; AB Lassman; R Merrell; Martin van den Bent; N Butowski; Z Lwin; H Wheeler; L Fichtel; AM Scott; EJ Gomez; J Fischer; H Mandich; H (Hong) Xiong; H J Lee; WP Munasinghe; LA Roberts-Rapp; PJ Ansell; KD Holen; P Kumthekar

doi:10.1093/neuonc/nox202

Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma

HK Gan, DA Reardon, AB Lassman, R Merrell, Martin van den Bent, N Butowski, Z Lwin, H Wheeler, L Fichtel, AM Scott, EJ Gomez, J Fischer, H Mandich, H (Hong) Xiong, H J Lee, WP Munasinghe, LA Roberts-Rapp, PJ Ansell, KD Holen, P Kumthekar

Neurology

Research output: Contribution to journal › Article › Academic › peer-review

45 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	838-847
Number of pages	10
Journal	Neuro-Oncology
Volume	20
Issue number	6
DOIs	https://doi.org/10.1093/neuonc/nox202
Publication status	Published - 2018

Access to Document

10.1093/neuonc/nox202

http://hdl.handle.net/1765/107311

Cite this

Gan, HK., Reardon, DA., Lassman, AB., Merrell, R., van den Bent, M., Butowski, N., Lwin, Z., Wheeler, H., Fichtel, L., Scott, AM., Gomez, EJ., Fischer, J., Mandich, H., Xiong, H., Lee, H. J., Munasinghe, WP., Roberts-Rapp, LA., Ansell, PJ., Holen, KD., & Kumthekar, P. (2018). Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma. Neuro-Oncology, 20(6), 838-847. https://doi.org/10.1093/neuonc/nox202

@article{ec30da2bc3384a0596f0d9d40feddb11,

title = "Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma",

author = "HK Gan and DA Reardon and AB Lassman and R Merrell and {van den Bent}, Martin and N Butowski and Z Lwin and H Wheeler and L Fichtel and AM Scott and EJ Gomez and J Fischer and H Mandich and Xiong, {H (Hong)} and Lee, {H J} and WP Munasinghe and LA Roberts-Rapp and PJ Ansell and KD Holen and P Kumthekar",

year = "2018",

doi = "10.1093/neuonc/nox202",

language = "Undefined/Unknown",

volume = "20",

pages = "838--847",

journal = "Neuro-Oncology",

issn = "1522-8517",

publisher = "Oxford University Press",

number = "6",

}

Gan, HK, Reardon, DA, Lassman, AB, Merrell, R, van den Bent, M, Butowski, N, Lwin, Z, Wheeler, H, Fichtel, L, Scott, AM, Gomez, EJ, Fischer, J, Mandich, H, Xiong, H, Lee, HJ, Munasinghe, WP, Roberts-Rapp, LA, Ansell, PJ, Holen, KD & Kumthekar, P 2018, 'Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma', Neuro-Oncology, vol. 20, no. 6, pp. 838-847. https://doi.org/10.1093/neuonc/nox202

TY - JOUR

T1 - Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma

AU - Gan, HK

AU - Reardon, DA

AU - Lassman, AB

AU - Merrell, R

AU - van den Bent, Martin

AU - Butowski, N

AU - Lwin, Z

AU - Wheeler, H

AU - Fichtel, L

AU - Scott, AM

AU - Gomez, EJ

AU - Fischer, J

AU - Mandich, H

AU - Xiong, H (Hong)

AU - Lee, H J

AU - Munasinghe, WP

AU - Roberts-Rapp, LA

AU - Ansell, PJ

AU - Holen, KD

AU - Kumthekar, P

PY - 2018

Y1 - 2018

U2 - 10.1093/neuonc/nox202

DO - 10.1093/neuonc/nox202

M3 - Article

SN - 1522-8517

VL - 20

SP - 838

EP - 847

JO - Neuro-Oncology

JF - Neuro-Oncology

IS - 6

ER -